There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rani Therapeutics Holdings (RANI – Research Report), Warby Parker (WRBY – Research Report) and Adaptive Biotechnologies (ADPT – Research Report) with bullish sentiments.
Rani Therapeutics Holdings (RANI)
BTIG analyst Julian Harrison maintained a Buy rating on Rani Therapeutics Holdings on May 10 and set a price target of $14.00. The company’s shares closed last Friday at $6.31.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of
Currently, the analyst consensus on Rani Therapeutics Holdings is a Strong Buy with an average price target of $11.50, representing a 72.9% upside. In a report issued on May 7, Stifel Nicolaus also maintained a Buy rating on the stock with a $10.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Warby Parker (WRBY)
BTIG analyst Janine Stichter maintained a Buy rating on Warby Parker on May 10 and set a price target of $18.00. The company’s shares closed last Friday at $14.79.
According to TipRanks.com, Stichter is a 4-star analyst with an average return of
Warby Parker has an analyst consensus of Moderate Buy, with a price target consensus of $17.10, representing a 13.7% upside. In a report issued on May 2, Telsey Advisory also maintained a Buy rating on the stock with a $19.00 price target.
Adaptive Biotechnologies (ADPT)
BTIG analyst Mark Massaro maintained a Buy rating on Adaptive Biotechnologies on May 10 and set a price target of $6.00. The company’s shares closed last Friday at $3.50.
According to TipRanks.com, Massaro is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Adaptive Biotechnologies has an analyst consensus of Moderate Buy, with a price target consensus of $6.33, a 77.3% upside from current levels. In a report issued on May 8, J.P. Morgan also maintained a Buy rating on the stock with a $5.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RANI:
- Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024
- Rani Therapeutics price target raised to $14 from $7 at BTIG
- Rani Therapeutics price target raised to $13 from $12 at H.C. Wainwright
- Rani Therapeutics reports Q1 EPS (29c), consensus (20c)
- Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update
